As filed with the Securities and Exchange Commission on March 16, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM S-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
________________
PRELUDE THERAPEUTICS INCORPORATED
(Exact name of Registrant as specified in its charter)
Delaware |
| 81-1384762 |
(State or other jurisdiction of |
| (I.R.S. Employer |
incorporation or organization) |
| Identification Number) |
200 Powder Mill Road
Wilmington, Delaware 19803
(302) 467-1280
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
(Full title of the plans)
Kris Vaddi, Ph.D.
Chief Executive Officer
Prelude Therapeutics Holdings
200 Powder Mill Road
Wilmington, Delaware 19803
(302)467-1280
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Effie Toshav, Esq. Robert Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP San Francisco, California 94104 |
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ |
Non-accelerated filer |
| ☒ |
| Smaller reporting company |
| ☒ |
|
|
|
| Emerging growth company |
| ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
Title of Each Class of Securities to be Registered | Amount to be Registered(1) | Proposed Maximum Offering Price Per Share | Proposed Maximum Aggregate Offering Price | Amount of Registration Fee |
Common Stock, par value $0.0001 per share |
|
|
|
|
-- 2020 Equity Incentive Plan | 2,185,283 (2) | $57.28 (3) | $125,173,011 | $13,657 |
-- 2020 Employee Stock Purchase Plan | 437,056 (4) | $48.68 (5) | $21,275,887 | $2,322 |
Total | 2,622,339 |
| $146,448,898 | $15,979 |
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that becomes issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock. |
(2) | Represents additional shares to be registered and available for grant under the 2020 Equity Incentive Plan (“2020 EIP”) resulting from the annual 5% automatic increase in the number of authorized shares available for issuance under the 2020 EIP. |
(3) | Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $57.28 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Stock Market LLC on March 12, 2021. |
(4) | Represents additional shares to be registered and available for grant under the 2020 Employee Stock Purchase Plan (“2020 ESPP”) resulting from the annual 1% automatic increase in the number of authorized shares available for issuance under the 2020 ESPP. |
(5) | Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $48.68 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Stock Market LLC on March 12, 2021, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2020 ESPP. |
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Prelude Therapeutics Incorporated (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (a) 2,185,283 additional shares of common stock available for issuance under the Registrant’s 2020 EIP, pursuant to the provision of the 2020 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance and (b) 437,056 additional shares of common stock available for issuance under the Registrant’s 2020 ESPP, pursuant to the provision of the 2020 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance.
In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2020 EIP and 2020 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on September 25, 2020 (Registration No. 333-249032), to the extent not superseded hereby.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:
| (a) | the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 16, 2021 pursuant to Section 13 of the Exchange Act; |
| (b) | the Registrant’s Current Reports on Form 8-K filed with the Commission on January 28, 2021 and March 8, 2021; |
| (c) | all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and |
| (d) | the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-39527) filed on September 16, 2020 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description. |
All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 8. Exhibits.
The following exhibits are filed herewith:
|
|
|
|
|
|
|
|
| Incorporated by Reference | Filed | |||||
Number | Exhibit Description | Form | File No. | Exhibit | Filing Date | Herewith |
|
|
|
|
|
|
|
|
|
4.1 | 10-Q | 001-39527 | 3.1 | 11/10/2020 |
|
| |
|
|
|
|
|
|
|
|
4.2 | 10-Q | 001-39527 | 3.2 | 11/10/2020 |
|
| |
|
|
|
|
|
|
|
|
4.3 | S-1/A | 333-248628 | 4.1 | 9/16/2020 |
|
| |
|
|
|
|
|
|
|
|
5.1 |
|
|
|
| X |
| |
|
|
|
|
|
|
|
|
23.1 |
|
|
|
| X |
| |
|
|
|
|
|
|
|
|
23.2 | Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm |
|
|
|
| X |
|
|
|
|
|
|
|
|
|
24.1 | Power of Attorney (included on the signature page to this Registration Statement) |
|
|
|
| X |
|
|
|
|
|
|
|
|
|
99.1 | 2020 Equity Incentive Plan and forms of award agreements thereunder | S-1/A | 333-248628 | 10.3 | 9/21/2020 |
|
|
|
|
|
|
|
|
|
|
99.2 | 2020 Employee Stock Purchase Plan and forms of award agreements thereunder | S-1/A | 333-248628 | 10.4 | 9/21/2020 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on this 16th day of March, 2021.
PRELUDE THERAPEUTICS INCORPORATED
|
|
|
| By: | /s/ Krishna Vaddi |
|
| Krishna Vaddi |
|
| Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kris Vaddi and Brian Piper, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
|
|
|
|
|
|
| ||
Name |
| Title |
| Date |
|
| ||
|
|
|
|
|
| |||
/s/ Krishna Vaddi Krishna Vaddi, Ph.D. |
| Chief Executive Officer and Director (Principal Executive Officer) |
| March 16, 2021 | ||||
|
|
|
|
|
| |||
/s/ Brian Piper Brian Piper, M.B.A. |
| Chief Financial Officer (Principal Financial and Accounting Officer) |
| March 16, 2021 |
| |||
|
|
|
|
|
| |||
/s/ Paul A. Friedman Paul A. Friedman |
| Director |
| March 16, 2021 |
| |||
|
|
|
|
|
| |||
/s/ David Bonita David Bonita, M.D.
|
| Director |
| March 16, 2021 | ||||
/s/ Mardi C. Dier Mardi C. Dier |
| Director |
| March 16, 2021 | ||||
/s/ Julian Baker Julian Baker |
| Director |
| March 16, 2021 | ||||
/s/ Victor Sandor Victor Sandor, M.D.C.M. |
| Director |
| March 16, 2021 |